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Summary
Marshall syndrome is a rare, autosomal dominant skel-
etal dysplasia that is phenotypically similar to the more
common disorder Stickler syndrome. For a large kindred
with Marshall syndrome, we demonstrate a splice-do-
nor–site mutation in the COL11A1 gene that cosegre-
gates with the phenotype. The G1rA transition causes
in-frame skipping of a 54-bp exon and deletes amino
acids 726–743 from the major triple-helical domain of
the a1(XI) collagen polypeptide. The data support the
hypothesis that the a1(XI) collagen polypeptide has an
important role in skeletal morphogenesis that extends
beyond its contribution to structural integrity of the car-
tilage extracellular matrix. Our results also demonstrate
allelism ofMarshall syndrome with the subset of Stickler
syndrome families associatedwithCOL11A1mutations.
Introduction
Craniofacial morphogenesis is a complex process in
which unique bony structures are formed around the
developing brain (Sperber and Machin 1994; Johnston
and Bronsky 1995; Schilling 1997). The recent eluci-
dation of the molecular basis of several osteochondro-
dysplasias has laid the foundation for a better under-
standing of the embryologic development of the skull.
Mutations have been identified in genes encoding
growth-factor receptors, transcription factors, and struc-
tural proteins. Examples include defects of the fibroblast
growth factor receptor (FGFR) gene family, in the chon-
drodysplasias (reviewed by Gorlin 1997); defects of
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FGFR3 and MSX2, in isolated craniosynostoses (Ma et
al. 1996; Muenke et al. 1997); defects of TWIST (How-
ard et al. 1997), CBFA1 (Lee et al. 1997), and GLI3
(Vortkamp et al. 1991); and defects of type II collagen,
in the spondyloepiphyseal dysplasia congenita spectrum
(Spranger et al. 1994).
Marshall syndrome (MIM 154780) is an autosomal
dominant craniofacial disorder characterized by hypo-
plasia of the maxilla, nasal bones, and frontal sinuses,
as well as calvarial thickening, myopia, early-onset cat-
aracts, and sensorineural hearing loss (Marshall 1958).
Some of these clinical features are shared by individuals
with Stickler syndrome (hereditary arthro-ophthalm-
opathy), leading to the suggestion that the conditions
may be allelic (Cohen 1974). Stickler syndrome exhibits
genetic heterogeneity, and mutations in the genes en-
coding all three a-chains of type XI collagen (COL11A1,
COL11A2, andCOL2A1) have been reported (Spranger
et al. 1994; Vikkula et al. 1995; Richards et al. 1996).
Using a candidate-gene approach, we have excluded
linkage of the Marshall syndrome phenotype to
COL11A2 and COL2A1 and have established linkage
to the COL11A1 locus. We also report a splice-do-
nor–site mutation in COL11A1 that cosegregates with
the clinical phenotype in a large family with Marshall
syndrome.
Subjects and Methods
Analysis of the Marshall Syndrome Family
Members of the study family were ascertained at the
University of Michigan Medical Center by a clinical ge-
neticist, an ophthalmologist, and an otolaryngologist.
After approval by the University of Michigan Institu-
tional Review Board, informed consent was obtained
from each study participant.
DNA was extracted from peripheral blood leukocytes
by use of the PureGene DNA isolation kit (Gentra Sys-
tems). Individuals were typed for the following loci:
COL2A1 (Berg and Olaisen 1993); COL11A2 (Vikkula
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Table 1
Primers Complementary to the COL11A1 Coding
Sequence
Primer(s) Nucleotides
1F 1–20
11F 129–148
2F 688–707
12F, 12R 1093–1113
3F, 3R 1400–1419
13R 1716–1735
17F 1746–1765
4F, 4R 2011–2030
2161F 2161–2180
14F 2317–2336
18F, 18R 2341–2360
5F, 5R 2711–2731
2956R 2937–2956
19F, 19R 3081–3100
16F, 16R 3255–3275
6F, 6R 3540–3560
20F, 20R 3852–3871
3928F 3928–3947
4027R 4007–4027
7F, 7R 4180–4199
8F, 8R 4831–4851
8R2 4840–4860
5104R 5084–5104
9R 5543–5563
NOTE.—Nucleotide numbers correspond to the cDNA
sequence (GenBank J04177 and J05407). F  sense pri-
mer; and R  antisense primer.
et al. 1995); D1S429, D1S495, D1S239, D1S248,
D6S105, and D6S276 (Dib et al. 1996); and D18S1001
and D18S1002 (Griffith et al. 1996). For detection of
microsatellite-marker products, one PCR primer (Re-
search Genetics) was 5′ end-labeled with g-[32P]ATP.Am-
plifications were performed by use of Taq polymerase
(Boehringer Mannheim), with an initial denaturation for
3 min at 94C, followed by 25 cycles of 1 min at 94C,
1 min at 55C, 1 min at 72C, and a final extension of
10 min at 72C, in an MJ Research PTC-100 thermal
cycler. Amplification products were visualized by auto-
radiography, after electrophoresis on 6% polyacryl-
amide gels containing 7M urea.
Mapping of COL11A1 and Identification of
Closely Linked Markers
A human genomic phage clone was isolated by library
screening with a 2.5-kb COL11A1 cDNA probe (Ber-
nard et al. 1988). Sequence analysis identified a (CA)n
simple-sequence repeat that can be amplified from hu-
man genomic DNAwith primers 5′-TTT ATGTCTTGT
TCT GTT TGA-3′ (sense) and 5′-CTT AAT GGA GAA
TTA GAA TGG-3′ (antisense). Thirty-two informative
CEPH pedigrees were analyzed. Pairwise linkage anal-
yses were performed between COL11A1 and loci on
human chromosome 1, from the CEPH database
(www.cephb.fr), by use of the CLODSCORE portion of
the LINKAGE programs (version 5.10), kindly supplied
by Dr. Jurg Ott (Lathrop et al. 1984). The sex-specific
recombination rates for males (vm) and those for females
(vf) were set to be equal for the analyses. Locus-order
calculations were done by use of CILINK, and final order
testing was done by comparison of the location scores
for all the loci in their predicted order and then testing
of the inverted orders, also by use of CILINK.
Reverse-Transcription (RT) PCR
Trizol reagent (Gibco BRL) was used to extract total
RNA from primary cultures of dermal fibroblasts de-
rived from individual II-1. First-strand cDNA products
were prepared from 1 mg total RNA separately with
oligo(dT) primer or random hexamer primers, by use of
the SuperScript system (Gibco BRL). Overlapping cDNA
fragments were generated by nested PCR amplification
of the resulting RT products. The first-round PCR prim-
ers, listed in table 1, were the following sense (“F”)/
antisense (“R”) pairs: 1F/13R, 12F/5R, 17F/19R, 14F/
20R, 18F/7R, 6F/5104R, and 7F/9R. Two microliters of
RT products were amplified in 50 ml reaction volumes
with Taq polymerase. Enzyme was added after initial
denaturation for 4 min at 95C and cooling to 80C for
1 min, followed by 29 cycles of 40 s at 95C; 40 s at
52C (primer pair 1F/13R), 58C (primer pairs 12F/5R,
14F/20R, 6F/5104R, and 7F/9R), or 64C (primer pairs
17F/19R and 18F/7R); 3 min at 72C; and a final ex-
tension of 10 min at 72C. Nested second-round am-
plifications were performed similarly, to yield smaller
fragments internal to each of the first-round products.
Two microliters of first-round products were added as
substrate for each 50-ml nested PCR reaction. The cy-
cling parameters, with the corresponding primer pairs
indicated parenthetically, included initial heating to 95C
for 4 min; 40 s at 95C; 40 s at 54C (2F/3R), 58C
(11F/12R, 12F/13R, 3F/4R, 4F/5R, 2161F/2956R, and
7F/5104R), 62C (5F/6R, 19F/20R, 16F/7R, 20F/8R,
20F/8R2, and 8F/9R), or 66C (17F/18R and 18F/16R);
and 1 min 20 s at 72C, for 35 cycles, with an extension
of 10 min at 72C.
Mutation Detection in cDNA by Conformation-
Sensitive Gel Electrophoresis
Second-round RT-PCR products were analyzed di-
rectly by conformation-sensitive gel electrophoresis, as
described elsewhere (Ganguly et al. 1993; Raman et al.
1997). PCR products were digested with the restriction
enzymes ApaI, EcoRI, FokI, HhaI, HinfI, HpaII, RsaI,
or StyI, to produce 200–600-bp fragments for analysis.
The StyI-digestion fragments of the 20F/8R2 PCR prod-
uct derived from individual II-1 were excised from an
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agarose gel and were purified with Qiaex II (Qiagen),
for sequencing. Cycle sequencing was performed by use
of ThermoSequenase (Amersham), according to the
manufacturer’s instructions.
Mutation Detection in Genomic DNA
Primers 3928F and 4027R (table 1) were designed
from the cDNA sequence flanking the downstream
boundary of the 54-bp deleted segment and were used
to amplify genomic DNA from individual II-1. The 1-
kb amplification product was excised from a 1.5% aga-
rose gel and was purified with Qiaex II for cycle se-
quencing. Antisense primers COL INT R1 (5′-TTA ATG
AGT TGG GAA GGG AAA G-3′) and COL INT R2 (5′-
TTC GAA CCA CAG CTA AGA GTT G-3′) were de-
signed from the downstream intron sequences (nucleo-
tide positions 101 to 122 and 74 to 95,
respectively), for nested PCR with sense primer 3928F,
to amplify the exon/intron boundary from each family
member. The 3928F/COL INT R2 amplification prod-
ucts were analyzed directly by cycle sequencing.
Results
Marshall Syndrome Phenotype
The study family included nine living affected indi-
viduals, from three generations, with characteristic fea-
tures of Marshall syndrome (Marshall 1958; Ayme and
Preus 1984). These features included a markedly short
nose with flat root, depression of the nasal bridge, an-
teverted nostrils, and retracted midface (fig. 1A and 1B).
Four of the affected individuals had cleft palate and re-
current otitis media, which also were associated with
Pierre Robin sequence, in individual III-2. Four other
affected individuals had bifid uvula. No dental anom-
alies were observed. Affected individuals had myopia
and cataracts, which became apparent during the 1st
decade of life and were located in subcapsular, cortical,
nuclear, zonular, or anterior axial embryonic sites. Fluid
vitreous humor was present in all affected individuals
undergoing cataract surgery. Sensorineural hearing loss
was noted as early as 3 years of age, with gradual pro-
gression to moderate or severe levels by late adulthood.
Other features included short stature, relative to unaf-
fected family members, and stocky build. Early-onset
(i.e., 4th or 5th decade) symptomatic osteoarthritis af-
fecting the knees and lumbosacral spine and mild hy-
potrichosis and hypohidrosis were present in some af-
fected family members. Individual III-2 had mild
platyspondylia, and two individuals had bilateral upper-
extremity clinodactyly of the fourth and fifth digits. Ra-
diologic findings included severe hypoplasia of the max-
illa, nasal bones, and frontal sinuses (fig. 1C), calvarial
thickening and intracranial calcifications (fig. 1D), and
narrowed joint spaces, with osteophytic degeneration in
the hips (fig. 1E) and knees (fig. 1F).
Linkage Mapping of COL11A1 to Human
Chromosome 1p21
Amplification of genomic DNA from 50 normal in-
dividuals, by use of PCR primers flanking a (CA)n repeat
in the COL11A1 gene, identified six alleles 154–170 bp
in size. Allele frequencies were .06–.22, with an observed
heterozygosity of .70. The genotypes of CEPH pedigree
members 1331-01 and 1331-02 were 154/170 and 154/
162, respectively. COL11A1 showed no recombination
with markers D1S429, D1S495, D1S239, and D1S248
(LOD score 111.74). The most likely locus order is
AMY2B–2 cM–(COL11A1, D1S429, D1S495,
D1S239, D1S248)–5 cM–D1S221, with odds of 7#
for the next most likely order. These data confirm610
the previous mapping of COL11A1 to human chro-
mosome 1p21 by FISH analysis (Henry et al. 1988), and
is consistent with the linkage of Amy2 and COL11a1
on mouse chromosome 3 (Li et al. 1995).
Linkage and Haplotype Analysis of the Marshall
Syndrome Family
We tested four candidate genes for linkage toMarshall
syndrome: COL2A1, COL11A1, COL11A2, and the
human orthologue of the mouse craniofacial mutant
Tg9257. At least one obligatory recombination was ob-
served with the COL2A1 gene VNTR (Berg and Olaisen
1993), the Tg9257 markers D18S1001 and D18S1002
(Griffith et al. 1996), and the COL11A2 flanking mark-
ers D6S105 and D6S276 (data not shown). In contrast,
there was no recombination between the COL11A1
marker D1S248 and Marshall syndrome, in 12 infor-
mative meioses (fig. 2). D1S206, D1S239, D1S429, and
D1S495 also segregated concordantly with the pheno-
type. Thus, theMarshall syndrome locus is closely linked
to COL11A1.
Abnormal COL11A1 Transcript in Affected Individuals
Overlapping cDNA fragments corresponding to the
COL11A1 open reading frame were prepared by RT-
PCR using dermal fibroblast RNA from affected indi-
vidual II-1 (fig. 2) and from unaffected controls. Con-
formation-sensitive gel electrophoresis of RT-PCR prod-
ucts spanning the open reading frame detected a single
difference between the affected individual and the con-
trols: an extra band in the 1.1-kb RT-PCR product ob-
tained with primers 20F and 8R2 (table 1). Digestion of
this 1.1-kb cDNA fragment with FokI generated a
unique 513-bp fragment in the sample from the affected
individual (fig. 3). Comparison of the nucleotide se-
quence of the RT-PCR product from the patient and that
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Figure 1 Marshall syndrome phenotype of individual II-1. A and B, Photographs showing the short nose with flat root, sunken nasal
bridge, retruded midface, and mild orbital hypertelorism. C, Cranial radiograph showing hypoplastic nasal bones (arrowheads). D, Cranial
computed tomography showing intracranial calcifications (arrows). E and F, Radiographs of the hip (E) and knee (F), showing narrowing of
joint spaces and osteophytic changes.
from the controls revealed an internal 54-bp in-frame
deletion in the patient that corresponds to nucleotides
3924–3977 of the COL11A1 cDNA (numbered accord-
ing to GenBank accession nos. J04177 and J05407 [http:
//www.ncbi.nlm.nih.gov]; Bernard et al. 1988; Yoshioka
and Ramirez 1990). The deleted sequence encodes 18
amino acids, corresponding to residues 726–743 of the
triple-helical domain of the mature a1(XI) polypeptide
(Bernard et al. 1988).
Mutation Detection in Genomic DNA
To determine the molecular basis for the 54-bp de-
letion in the COL11A1 cDNA, genomic DNA was am-
plified with cDNA primers 3928F and 4027R (table 1),
flanking the 3′ end of the deleted sequence. The 1-kb
genomic amplification product from affected individual
II-1 was sequenced (GenBank accession no. AF017809).
Comparison with the cDNA demonstrated the presence
of two exons and one intron in the amplified fragment.
Downstream of the first exon, heterozygosity for a GrA
transition at the1 position of the splice-donor site was
detected (fig. 4, left panel). This mutation changes the
splice donor in the wild-type allele from the consensus-
site sequence GTAAGT to the nonconsensus sequence
ATAAGT (fig. 5A). The remaining sequence was iden-
tical in the two alleles. Genomic DNA from the other
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Figure 2 Pedigree showing linkage of Marshall syndrome phe-
notype with COL11A1 markers from chromosome 1p21.
Figure 3 AbnormalCOL11A1 transcript inMarshall syndrome.
The RT-PCR products amplified with primers 20F and 8R2 (table 1),
from affected individual II-1 and from an unaffected control, were
digested with FokI and were separated by agarose-gel electrophoresis.
A novel restriction fragment present only in the affected individual is
indicated by an arrow. The relative mobilities of molecular-weight
markers (FX174/HaeIII) are shown to the left.
family members was tested for the splice-site mutation
by sequencing the amplified PCR product. Cosegrega-
tion of the mutation with the disorder is demonstrated
in figure 4 (right panel). Using MLINK (Lathrop et al.
1984), with , we obtained a LOD score ofq  .0001
3.31 (at ), between the disease phenotype and thev  0
mutant allele.
Discussion
Exon skipping due to the splice-site mutation in this
Marshall syndrome kindred is predicted to cause an
18–amino-acid deletion in the major triple-helical do-
main of the mature a1(XI) polypeptide (fig. 5B). Al-
though determination of the genomic organization of
COL11A1 is incomplete, the position of the 54-bp se-
quence that is deleted from the patient cDNA corre-
sponds precisely to exon 49 in the closely related fibrillar
collagen gene COL5A1 (Takahara et al. 1995). Muta-
tions of the consensus G at the1 position of the splice-
donor site frequently are associated with exon skipping
(Horowitz and Krainer 1994). Similar exon-skipping
mutations have been described in other fibrillar collagen
genes (Kuivaniemi et al. 1997), including COL11A2
(Vikkula et al. 1995) and COL2A1 (Tiller et al. 1995).
It has been proposed that the resulting mutant polypep-
tides associate with other a-chains via the intact C-pro-
peptide domain to form heterotrimers, but fail to form
a normal collagen triple helix. The incomplete formation
of the triple helix may exert a dominant-negative effect
on collagen synthesis, secretion, fibril assembly, or turn-
over (Tilstra and Byers 1994). The dominant mutation
in this Marshall syndrome kindred may act via this
mechanism.
The genetic relationship between Marshall syndrome
and Stickler syndrome has been debated extensively. The
kindred described here exhibits several clinical features
that serve to support its classification as a Marshall syn-
drome kindred: (1) persistence of the flat nasal root and
depressed nasal bridge through adulthood; (2) severe
hypoplasia of the nasal bones and frontal sinuses; (3)
calvarial thickening; and (4) intracranial calcifications
(Marshall 1958; Ayme and Preus 1984; Shanske et al.
1997). In addition, the short stocky build and round
face observed in affected members of this kindred are
most consistent with Marshall syndrome.
Mutations in COL2A1, COL11A1, and COL11A2
have been reported in kindreds with Stickler syndrome
(Spranger et al. 1994; Vikkula et al. 1995; Richards et
al. 1996), indicating that some cases of Stickler syn-
drome are allelic with Marshall syndrome. Clinical pho-
tographs and cranial radiographs of affected individuals
with Stickler syndrome due to mutation at the
COL11A1 locus (Richards et al. 1996) or linked to the
COL11A1 locus (Sirka-Osada et al. 1996) have not been
published, and it is possible that their craniofacial phe-
notype may be closer to that of Marshall syndrome.
Molecular characterization of additional families with
both syndromes will be required to clarify their genetic
relationship.
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Figure 4 Genomic COL11A1 mutation. Left, Sequence of genomic DNA from noncoding strand of affected individual II-1, showing
heterozygosity for a CrT transition at position 1 of the downstream intron. Right, ddTTP–chain termination products (corresponding to
lane t in left panel) from sequence analysis of kindred members, showing cosegregation of the CrT transition with the phenotype.
Figure 5 A, Splice-donor–site mutation in COL11A1. The CrT
transition corresponds to a GrA transition in the coding strand, al-
tering the canonical GT dinucleotide of the consensus splice-donor–site
sequence at the exon (uppercase letters)–intron (lowercase letters)
boundary. B, Mutations in the a1(XI) collagen polypeptide. The sche-
matic diagram of the a1(XI) polypeptide illustrates the sites of the
18–amino-acid deletion in the Marshall syndrome kindred and the
Gly97Val missense mutation in the Stickler syndrome kindred reported
by Richards et al. (1996). Hatched areas indicate domains containing
Gly-X-Y repeat motifs that assemble into triple helices with other
collagen subunits.
A phenotypic spectrum has been described for mu-
tations in several collagen genes (Spranger et al. 1994;
Tilstra and Byers 1994) and in other genes expressed in
connective tissue (Oldridge et al. 1997). Genotype/phe-
notype correlations among allelic mutations can provide
insight into the functions of various protein domains. If
Marshall syndrome and Stickler syndrome are allelic, we
predict that COL11A1 mutations associated with the
Marshall syndrome phenotype will be more disruptive
to protein structure than those causing Stickler
syndrome.
The distinct craniofacial features observed inMarshall
syndrome suggest that, during development, the a1(XI)
polypeptide has a unique role distinct from that of the
other collagen polypeptides with which it forms heter-
otrimers. This hypothesis is consistent with the differ-
ences in expression patterns of these genes (Mayne et al.
1993; Lui et al. 1995; Yoshioka et al. 1995a; Tsumaki
et al. 1996), including the specific expression of
COL11A1 in developing nasal structures (Yoshioka et
al. 1995b). These genes also differ in tissue-specific al-
ternative splicing (Oxford et al. 1995; Yoshioka et al.
1995a; Zhidkova et al. 1995) and in their contribution
to heterotrimer assembly and heterotypic fibril forma-
tion, including the association of a1(XI) subunits with
a2(V) subunits to form heterotrimeric V/XI molecules
in noncartilaginous tissues such as bone and vitreous
humor (Niyibizi and Eyre 1989; Mayne et al. 1993).
Differences in the vitreoretinal phenotype among Stick-
ler syndrome kindreds that are linked or unlinked to the
COL2A1 locus have been observed (Snead et al. 1994).
In addition, unlike Stickler syndrome patients with mu-
tations in COL2A1 or COL11A1, there is no ocular
involvement in three Stickler syndrome families with
mutations in COL11A2 (Vikkula et al. 1995; Sirko-Os-
adsa et al., in press).
In addition to their well-documented role in estab-
lishing and maintaining structural integrity of connective
tissues, new roles for the fibrillar collagens are becoming
evident. In the mouse mutant chondrodysplasia (cho
gene), a null mutation of COL11A1 produces an au-
tosomal recessive lethal phenotype with nasomaxillary
hypoplasia and disturbances in the morphogenesis of
endochondral growth plates (Li et al. 1995). The phe-
notype of the Marshall syndrome kindred described here
demonstrates a similar role for COL11A1 in human
craniofacial development. The related defects in mouse
mutant Tg9257 suggests that its orthologous gene on
human chromosome 18q11 also may contribute to the
spectrum of human craniofacial disorders (Griffith et al.
1996). Continued biochemical and molecular studies of
human families and mouse models will further our un-
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derstanding of the complex processes involved in
cephalogenesis.
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